Stay updated with breaking news from Narcolepsy Type. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Preclinical data demonstrated significant activity at low doses of ORX750 in highly predictive translational models of Narcolepsy Type 1 - ORX750 advancing in IND-enabling studies; Clinical proof...
S.W. Black, T. Steinfeld, K. Gibson, G.R. Ott, E. Ratti, D. Grainger, M.A. Accardi, D.S. Hartman Centessa Pharmaceuticals, Inc., Boston, MA, United States, Centessa...
-- Successfully commenced U.S. commercial launch of LUMRYZ™-- -- Received final FDA approval for LUMRYZ with orphan drug exclusivity granted through May 1, 2030 -- -- Significant early progress on payor coverage, prescriber certifications and patient enrollments -- -- Management to host a conference call today at 8:30 a.m. ET -- DUBLIN, Ireland, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform
Trial Was Stopped Due to Hepatotoxicity and Consequently TAK-994 Program Terminated for Further Development In Patients with Narcolepsy Type 1, Oral Orexin Receptor 2 Agonist Demonstrated...
Centessa Pharmaceuticals (NASDAQ:CNTA – Get Rating) and Dermata Therapeutics (NASDAQ:DRMA – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. Profitability This table compares Centessa Pharmaceuticals and Dermata Therapeutics’ […]